GCORE
6.3.2024 09:06:31 CET | Business Wire | Press release
Gcore, the global edge AI, cloud, network, and security solutions provider, today announced the acquisition of StackPath’s web application and API protection (WAAP) solution. A highly regarded security product for protecting applications, the new acquisition will provide Gcore customers with an enhanced, enterprise-grade security solution, incorporating web application firewall (WAF), API security, bot protection, and Layer-7 DDoS mitigation at the edge.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240306076612/en/
Gcore is the global edge AI, cloud, network, and security solutions provider. (Graphic: Gcore)
The acquisition marks a pivotal advancement in Gcore’s mission to deliver comprehensive, edge security services to its customers worldwide. The WAAP will be integrated into Gcore’s security product lineup by Q3 2024.
StackPath WAAP was recognised as a cloud WAF leader by independent security solutions assessor, SecureIQLab in a report comparing the security and operational efficiency of multiple cloud WAF solutions.
Andre Reitenbach, CEO at Gcore, comments: “The acquisition of StackPath WAAP marks a significant milestone in our strategic roadmap, underscoring our commitment to continuous innovation of our solutions and edge infrastructure. With its outstanding reputation for quality, StackPath WAAP stands as a premier solution in the market. Its integration will further strengthen our customers’ application and API security and provide them with enhanced defences against application-layer DDoS attacks at the edge”.
Gcore’s extensive edge network spans over 160 points of presence, delivering fast, reliable, and secure digital experiences worldwide. By leveraging its edge network, Gcore brings protection closer to the end user. This approach reduces latency, scales seamlessly against large-scale DDoS attacks, protects against common vulnerabilities, safeguards critical API endpoints, and leverages real-time threat intelligence. A key advantage of StackPath WAAP is its ability to leverage machine learning to detect and mitigate malicious behaviour. As Gcore incorporates the product into its portfolio, it will enhance its capabilities with AI-driven WAF, enabling advanced identification of HTTP patterns to provide enhanced protection and improve mitigation for zero-day attacks.
Gcore will maintain the rapid setup and out-of-the-box features that have made StackPath WAAP easily configurable, and add capabilities including customisation, advanced threat identification, and real-time analytics. Integration is scheduled by Q3 2024, with an early-access version available for customer evaluation in the meantime. Flexible pricing plans will meet the needs of customers based on usage.
“We’re passionate about security in the cloud and proud of the WAAP we built at StackPath,” said Kip Turco, Chief Executive Officer for StackPath. “When we decided to focus even more specifically on our latency-sensitive, highly distributed edge-computing platform, we knew Gcore would be the perfect home for the continuing innovation of this next-gen WAAP. We look forward to partnering with Gcore even more in the ongoing evolution of cloud, edge, and the security solutions the industry needs.”
About Gcore
Gcore is a global edge AI, cloud, network, and security solutions provider. Headquartered in Luxembourg, Gcore manages its own IT infrastructure across six continents, with leading network performance in Europe, Africa, and LATAM.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240306076612/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom